Table 5. Comparison of clinical characteristics according to LDL-cholesterol SD < median or ≥ median in CKD stage 3 patients.
| Characteristics | LDL-cholesterol SD < median (n = 135) | LDL-cholesterol SD ≥ median (n = 135) | p | All (n = 270) |
|---|---|---|---|---|
| Age (year) | 65.6 ± 11.8 | 62.8 ± 11.7 | 0.051 | 64.2 ± 11.8 |
| Male gender (%) | 76.3 | 76.3 | 1.000 | 76.3 |
| Smoking history (%) | 34.3 | 36.3 | 0.736 | 35.3 |
| Diabetes mellitus (%) | 48.9 | 68.1 | 0.001 | 58.5 |
| Hypertension (%) | 88.1 | 88.1 | 0.982 | 88.1 |
| Coronary artery disease (%) | 8.2 | 7.5 | 0.834 | 7.9 |
| Cerebrovascular disease (%) | 9.6 | 3.4 | 0.256 | 7.8 |
| Laboratory parameters | ||||
| Albumin (g/dL) | 4.2 ± 0.2 | 4.1 ± 0.4 | 0.112 | 4.2 ± 0.3 |
| Fasting glucose (mg/dL) | 116.8 ± 37.1 | 140.7 ± 65.8 | <0.001 | 128.8 ± 54.7 |
| Hemoglobin (g/dL) | 12.9 ± 1.9 | 13.0 ± 1.9 | 0.718 | 13.0 ± 1.9 |
| Baseline eGFR (mL/min/1.73 m2) | 40.1 ± 7.0 | 39.9 ± 7.0 | 0.764 | 40.0 ± 6.9 |
| Total calcium (mg/dL) | 9.6 ± 0.5 | 9.5 ± 0.6 | 0.678 | 9.6 ± 0.6 |
| Phosphorous (mg/dL) | 3.5 ± 0.5 | 3.6 ± 0.5 | 0.769 | 3.6 ± 0.5 |
| Uric acid (mg/dL) | 7.7 ± 1.9 | 7.9 ± 2.0 | 0.413 | 7.8 ± 1.9 |
| UPCR (mg/g) | 748.6 ± 1079.2 | 1535.9 ± 2398.4 | 0.004 | 1144.3 ± 1899.5 |
| Medications | ||||
| ACEI and/or ARB use (%) | 71.9 | 72.6 | 0.892 | 72.2 |
| β-blocker use (%) | 17.0 | 14.8 | 0.618 | 15.9 |
| Calcium channel blocker use (%) | 35.6 | 28.1 | 0.191 | 31.9 |
| Diuretics use (%) | 5.2 | 7.4 | 0.452 | 6.3 |
| Statin use (%) | 48.9 | 14.8 | <0.001 | 31.9 |
Abbreviations are same as Table 1.